Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) | RFA AG 24 001

Opportunity Information: Apply for RFA AG 24 001

The Alzheimer’s Disease Research Centers (ADRC) program (RFA-AG-24-001) is a National Institutes of Health (NIH) grant opportunity run by the National Institute on Aging (NIA) to support institutions that want to establish a new ADRC or renew an existing one. These awards use the P30 center grant mechanism and are specifically labeled “Clinical Trial Not Allowed,” meaning the center award itself is not intended to run clinical trials as part of the funded activities under this announcement. The overall purpose is to strengthen a nationwide network of major medical and research institutions that function as shared, national resources for Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) research, and to accelerate the translation of scientific progress into better diagnosis, care practices, and ultimately strategies to treat and possibly prevent AD/ADRD.

At a practical level, the FOA is aimed at building or sustaining comprehensive, coordinated research centers rather than isolated projects. An ADRC is expected to bring together multidisciplinary expertise, infrastructure, and shared resources that enable investigators to conduct high-quality AD/ADRD research efficiently and collaboratively. The announcement emphasizes that ADRCs are not meant to operate in isolation; they are expected to actively collaborate and coordinate with other NIH-funded programs and investigators, reinforcing the idea of a connected national network. This coordination aspect typically matters because AD/ADRD research relies on standardized approaches, shared data resources, harmonized clinical and research methods, and cross-site collaborations that make findings more comparable and broadly useful.

The program’s public health and translational focus is clear: NIA wants ADRCs to help move research advances into real-world impact. That includes improving diagnostic approaches and clinical care, supporting research that clarifies disease mechanisms and progression, and enabling studies that inform prevention or treatment strategies (even if the center grant itself does not support clinical trials). In other words, the center is intended to be a platform that supports a broad range of AD/ADRD research and helps discoveries travel the full path from scientific insight to improved patient and caregiver outcomes.

Eligibility is broad and spans many organization types across the United States, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and certain tribal organizations; independent school districts; special district governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out several categories of institutions and organizations as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI), along with faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. While many U.S.-based entities can apply, non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. However, “foreign components,” as defined by the NIH Grants Policy Statement, are allowed, which typically means certain parts of the work may be conducted abroad under NIH rules when justified, even though the applicant organization itself must be U.S.-eligible.

This is a discretionary grant in the health funding category under CFDA 93.866. The original closing date listed is 2025-09-26. The posted award ceiling is $2,925,000. The FOA was created on 2023-01-11. Taken together, the opportunity is designed for institutions capable of running a mature, coordinated center-level effort that supports and connects investigators, resources, and collaborative research activity focused on AD and ADRD, while aligning with NIH expectations for national coordination, infrastructure-building, and translation of research into better clinical understanding and care.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2023-01-11.
• Applicants must submit their applications by 2025-09-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $2,925,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AG 24 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: